Antiphospholipid antibodies in critical illness

Critical Care Medicine

Volumn 38, Issue SUPPL. 2, 2010, Pages

  Dentali, Francesco ^a   Crowther, Mark ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Anticoagulation; Antiphospholipid syndrome; Risk; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HEPARIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; PLACEBO; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CRITICAL ILLNESS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MATERNAL MORBIDITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; STROKE; THROMBOSIS PREVENTION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 74949100569     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181c9e363     Document Type: Review

References (71)

1. Wilson WA, Gharavi AE, Koike T, et al: International consensus statement on preliminary classification criteria for definite an-tiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999; 42:1309-1311
2. Miyakis S, Lockshin MD, Atsumi T, et al: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306
3. Ruffatti A, Olivieri S, Tonello M, et al: Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008; 6:1693-1696
4. Triplett DA: Antiphospholipid antibodies. Arch Pathol Lab Med 2002; 126:1424-1429
5. Brandt JT, Triplett DA, Alving B, et al: Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74:1185-1190
6. Tripodi A, Chantarangkul V, Clerici M, et al: Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost 2002; 88: 583-586
7. Harris EN, Pierangeli SS: Revisiting the an-ticardiolipin test and its standardization. Lupus 2002; 11:269-275
8. Harris EN: Special report. The Second International Anticardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990; 94:476-484
9. Favaloro EJ, Wong RC, Silvestrini R, et al: A multilaboratory peer assessment quality assurance program-based evaluation of anti-cardiolipin antibody, and beta2-glycoprotein I antibody testing. Semin Thromb Hemost 2005; 31:73-84
10. Galli M, Luciani D, Bertolini G, et al: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 2003; 101: 1827-1832
11. Gharavi AE, Sammaritano LR, Wen J, et al: Characteristics of human immunodeficiency virus and chlorpromazine induced antiphos-pholipid antibodies: Effect of beta 2 glycop-rotein I on binding to phospholipid. J Rheu-matol 1994; 21:94-99
12. Canoso RT, de Oliveira RM, Nixon RA: Neu-rolepticassociated autoantibodies: A prevalence study. Biol Psychiatry 1990; 27: 863-870
13. Roubey RA: Antiphospholipid syndrome: antibodies and antigens. Curr Opin Hematol 2000; 7:316-320
14. Maiti SN, Balasubramanian K, Ramoth JA, et al: Beta-2-glycoprotein1- dependent macro-phage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members. J Biol Chem 2008; 283: 3761-3766
15. Kobayashi K, Matsuura E, Liu Q, et al: A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macro-phages. J Lipid Res 2001; 42:697-709
16. Shi T, Iverson GM, Qi JC, et al: Beta 2-gly-coprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped beta 2-glycoprotein I. Proc Natl Acad Sci USA 2004; 101: 3939-3944
17. de Laat B, Derksen RH, van Lummel M, et al: Pathogenic antibeta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107:1916-1924
18. Malia RG, Kitchen S, Greaves M, et al: Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76:101-107
19. Ieko M, Sawada KI, Koike T, et al: The putative mechanism of thrombosis in antiphos-pholipid syndrome: Impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies. Se-min Thromb Hemost 1999; 25:503-507
20. de LB, Eckmann CM, van SM, et al: Correlation between the potency of a beta2-glycop-rotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagul Fibrinolysis 2008; 19:757-764
21. Kinev AV, Roubey RA: Tissue factor in the antiphospholipid syndrome. Lupus 2008; 17: 952-958
22. Monroe DM, Key NS: The tissue factor-factor VIIa complex: Procoagulant activity, regulation, and multitasking. J Thromb Haemost 2007; 5:1097-1105
23. Cuadrado MJ, Lo'pez-Pedrera C, Khamashta MA, et al: Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40:834-841
24. Dobado-Berrios PM, Lo'pez-Pedrera C, Velasco F, et al: Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999; 82: 1578-1582
25. Reverter JC, Tassies D, Font J, et al: Hyper-coagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol 1996; 16:1319-1326
26. Nojima J, Masuda Y, Iwatani Y, et al: Tissue factor expression on monocytes induced by anti-phospholipid antibodies as a strong risk factor for thromboembolic complications in SLE patients. Biochem Biophys Res Com-mun 2008; 365:195-200
27. Ritis K, Doumas M, Mastellos D, et al: A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006; 177: 4794-4802
28. Vila P, Hernandez MC, Lopez-Fernandez MF, et al: Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72: 209-213
29. Ginsberg JS, Wells PS, Brill-Edwards P, et al: Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691
30. Mateo J, Oliver A, Borrell M, et al: Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism: Results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444-451
31. Long AA, Ginsberg JS, Brill-Edwards P, et al: The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: A cross-sectional study. Thromb Haemost 1991; 66:520-524
32. Bruce IN, Clark-Soloninka CA, Spitzer KA, et al: Prevalence of antibodies to beta2-glycop-rotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: A single center study and literature review. J Rheumatol 2000; 27: 2833-2837
33. Wahl DG, Guillemin F, de Maistre E, et al: Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7:15-22
34. Janardhan V, Wolf PA, Kase CS, et al: Anti-cardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: The Framingham cohort and offspring study. Stroke 2004; 35:736-741
35. Ginsburg KS, Liang MH, Newcomer L, et al: Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117:997-1002
36. Naess IA, Christiansen SC, Cannegieter SC, et al: A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006; 4:44-49
37. Oshiro BT, Silver RM, Scott JR, et al: An-tiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87:489-493
38. Rai RS, Clifford K, Cohen H, et al: High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995; 10:3301-3304
39. Branch DW, Silver RM, Blackwell JL, et al: Outcome of treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience. Obstet Gynecol 1992; 80:614-620
40. Out HJ, Bruinse HW, Christiaens GC, et al: A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gy-necol 1992; 167:26-32
41. Kaul M, Erkan D, Sammaritano L, et al: Assessment of the 2006 revised antiphospho-lipid syndrome classification criteria. Ann Rheum Dis 2007; 66:927-930
42. Brouwer JL, Bijl M, Veeger NJ, et al: The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004; 104:143-148
43. Hudson M, Herr AL, Rauch J, et al: The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol 2003; 30:2385-2391
44. Petri M: Thrombosis and systemic lupus er-ythematosus: The Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 191-193
45. Crowther MA, Wisloff F: Evidence based treatment of the antiphospholipid syndrome II: Optimal anticoagulant therapy for thrombosis. Thromb Res 2005; 115:3-8
46. Schulman S, Svenungsson E, Granqvist S; Duration of Anticoagulation Study Group: Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembo-lism following anticoagulant therapy. Am J Med 1998; 104:332-338
47. Kearon C, Gent M, Hirsh J, et al: A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340:901-907 (Pubitemid 29141050)
48. Kearon C, Ginsberg JS, Kovacs MJ, et al: Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349:631-639 (Pubitemid 36975995)
49. Rosove MH, Brewer PM: Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117:303-308
50. Khamashta MA, Cuadrado MJ, Mujic F, et al: The management of thrombosis in the an-tiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993-997
51. Finazzi G, Brancaccio V, Moia M, et al: Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-536
52. Cervera R, Piette JC, Font J, et al: Antiphos-pholipid syndrome: clinical and immuno-logic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46:1019-1027 (Pubitemid 34303815)
53. Buller HR, Agnelli G, Hull RD, et al: Anti-thrombotic therapy for venous thromboem-bolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:401S-428S
54. Garcia DA, Khamashta MA, Crowther MA: How we diagnose and treat thrombotic man-ifestations of the antiphospholipid syndrome: A case-based review. Blood 2007; 110: 3122-3127
55. Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J Med 2002; 346:752-763
56. Trenfield S, Parmar K, Hunt BJ: Monitoring heparin in patients with a lupus anticoagulant: Detection of heparin resistance. J Thromb Haemost 2008; 6:1980-1982
57. Crowther MA, Ginsberg JS, Julian J, et al: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138
58. Finazzi G, Marchioli R, Brancaccio V, et al: A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3:848-853
59. Criado-García J, Fernandez-Puebla RA, Jimenez LL, et al: [Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become negative]. Rev Clin Esp 2008; 208:135-137
60. The APASS Writing Committee: Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291:576-584
61. Tenedios F, Erkan D, Lockshin MD: Cardiac involvement in the antiphospholipid syndrome. Lupus 2005; 14:691-696
62. Mohr JP, Thompson JL, Lazar RM, et al: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345:1444-1451
63. Brey RL, Chapman J, Levine SR, et al: Stroke and the antiphospholipid syndrome: Consen-sus meeting Taormina 2002. Lupus 2003; 12:508-513
64. Alarcon-Segovia D, Boffa MC, Branch W, et al: Prophylaxis of the antiphospholipid syndrome: A consensus report. Lupus 2003; 12: 499-503
65. Erkan D, Harrison MJ, Levy R, et al: Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56:2382-2391
66. Vivaldi P, Rossetti G, Galli M, Finazzi G: Severe bleeding due to acquired hypopro-thrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica 1997; 82:345-347
67. Asherson RA: The catastrophic antiphospho-lipid syndrome. J Rheumatol 1992; 19: 508-512
68. Bucciarelli S, Espinosa G, Cervera R, et al, for the CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies): Mortality in the catastrophic antiphos-pholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006; 54:2568-2576
69. Asherson RA, Cervera R, Piette JC, et al: Catastrophic antiphospholipid syndrome: Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77: 195-207
70. Kitchens CS: Thrombotic storm: When thrombosis begets thrombosis. Am J Med 1998; 104:381-385
71. Erkan D, Asherson RA, Espinosa G, et al: Long term outcome of catastrophic an-tiphospholipid syndrome survivors. Ann Rheum Dis 2003; 62:530-533